source
- Indivior ends Addex PAM collaboration as it prepares for Supernus mergerIndivior Pharmaceuticals has terminated its long‑standing partnership with Addex Therapeutics that focused on developing positive allosteric modulators (PAMs) for addiction treatment. The collabor…
- Kali Therapeutics pivots from Chinese drug acquisitions to focus on its own growing pipelineKali Therapeutics, the winner of the Endpoints 11 2026 competition, initially explored the possibility of purchasing drug candidates from China. The company ultimately chose to rely on its own res…